No Data
No Data
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
Revive Therapeutics Ltd. (RVV.CN) on Tuesday provided an update on its clinical study evaluating the safety and feasibility of oral psilocybin as a potential treatment for methamphetamine use disorder
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillami...
Revive Therapeutics to Submit Type C Meeting Request With FDA for Bucillamine to Treat Long COVID
Revive Therapeutics Ltd. (RVV.CN), a specialty life sciences company focused on the R&D of therapeutics for medical needs and rare disorders, on Tuesday said the FDA has advised it to submit a Type C
Revive Therapeutics To Submit Type C Meeting Request With FDA for Bucillamine to Treat Long COVID
Revive Therapeutics Provides Corporate Update
Revive Therapeutics Ltd. (RVV.CN), a specialty life sciences company focused on the R&D of therapeutics for medical needs and rare disorders, on Tuesday provided a corporate update on the research, c
Press Release: Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110
Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110 NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO